会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT
    • ALZHEIMER在生活中的疾病测定
    • US20160266149A1
    • 2016-09-15
    • US15167370
    • 2016-05-27
    • Hoau-Yan WangLindsay Burns Barbier
    • Hoau-Yan WangLindsay Burns Barbier
    • G01N33/68
    • G01N33/50G01N33/6896G01N33/94G01N2333/70571G01N2800/2821G01N2800/52
    • An assay for Alzheimer's disease pathology (AD) in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, TLR4-FLNA and/or α7nAChR-Aβ42 complex present as a protein-protein complex in a sample is determined and compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is determined and compared to an amount determined in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four of the six pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of the medicament less than the first determined amount indicates a favorable treatment prognosis.
    • 公开了一种活体患者中阿尔茨海默病病理学(AD)的测定法,其中在被捕获的FLNA捕获的蛋白质复合物中的α7nAChR或TLR4或Aβ捕获的蛋白质复合物或α7nAChR-FLNA,TLR4-FLNA和/或α7nAChR中的α7nAChR 确定样品中作为蛋白质 - 蛋白质复合物存在的-Aβ42复合物,并与来自不存在AD病理学的人的标准样品中的量进行比较。 大于标准样品的量表示AD病理学。 还公开了一种预测用于治疗药物的预测的方法,其中确定上述蛋白质或蛋白质复合物的量并将其与在与FLNA五肽结合并且含有至少四种 图6的六个药效团。 7-12。 在小于第一确定量的药物存在下测定的蛋白质或蛋白质复合物的量表明有利的治疗预后。
    • 7. 发明授权
    • Alzheimer's disease assay in a living patient
    • 阿尔茨海默病测定在一个活的病人
    • US09354223B2
    • 2016-05-31
    • US13942326
    • 2013-07-15
    • Hoau-Yan WangLindsay Burns Barbier
    • Hoau-Yan WangLindsay Burns Barbier
    • G01N33/50G01N33/94G01N33/68
    • G01N33/50G01N33/6896G01N33/94G01N2333/70571G01N2800/2821G01N2800/52
    • An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of medicament that is less than the first amount indicates a favorable treatment prognosis.
    • 公开了一种活体患者的阿尔茨海默氏病(AD)病理学测定法,其中在被捕获的蛋白质复合物或α7nAChR-FLNA或TLR4-FLNA中的α7nAChR或TLR4或α7nAChR或TLR4-FLNA和/ 或作为样品中蛋白质 - 蛋白质复合物存在的α7nAChR-A&bgr; 42复合物与来自不具有AD病理学的人的标准样品中的量进行比较。 大于标准样品的量表示AD病理学。 还公开了一种预测用于用药物进行治疗的预测的测定法,其中将上述蛋白质或蛋白质复合物的量与结合FLNA五肽并含有至少四种图1和2的药效学的药物存在下的量进行比较。 7-12。 在小于第一量的药物存在下测定的蛋白质或蛋白质复合物的量表明有利的治疗预后。